17 research outputs found
Quality of data regarding care seeking for ill or suspected ill neonates: all included studies.
<p>Abbreviations: CHW, community health worker; GP, government provider; IMNCI, integrated management of childhood and neonatal illnesses, NGC, nongovernmental consultants; NGD, nongovernmental dispensers; N/A, not available; PHC, primary health care; SHC, secondary health care; TH, traditional healer.</p
Characteristics of studies that describe care seeking for ill or suspected ill neonates.
a<p>Percentage reported as a proportion of all neonates with an illness or suspected illness reported by each study.</p>b<p>Data obtained via correspondence with corresponding author.</p><p>Abbreviations: C-RCT, cluster randomized controlled trial; CHW, community health worker; ENC, essential newborn care; ENCT, essential newborn care plus thermostat; N/A, not available.</p
Quality of data regarding care seeking for ill or suspected ill neonates: summary of included studies.
<p>Abbreviations: N/A, not available.</p
Community-based studies that describe type of care sought for ill or suspected ill neonates.
a<p>Percentage reported as a proportion of all neonates with an illness or suspected illness that were included in each study. Multiple responses regarding type of care sought were permitted, as described by included studies.</p><p>Abbreviations: C, control; ENC, essential newborn care; ENCT, essential newborn care plus thermostat; I, intervention; N/A, not available.</p
WHO/HAI antibiotic pricing data for treatment of neonatal sepsis by WHO region.
<p>Total cost is estimated for the course of treating a 3 kg neonatal child for 10 days. For capsular formulation, the assumption was reconstitution in sterile water. For oral suspension 10% wastage was assumed.</p><p>For vials, a shelf life of 24 hours was assumed for ceftriaxone. The data were from 2001 to 2013, and were not adjusted for inflation.</p>a<p>Data based on national surveys from: AFR (<i>n</i>β=β4), AMR (<i>n</i>β=β1).</p>b<p>Data based on national surveys from: AFR (<i>n</i>β=β8), AMR (<i>n</i>β=β2), EMR (<i>n</i>β=β9), SEAR (<i>n</i>β=β4), WPR (<i>n</i>β=β5).</p>c<p>Data based on national surveys from: AFR (<i>n</i>β=β15), AMR (<i>n</i>β=β9), EMR (<i>n</i>β=β13), SEAR (<i>n</i>β=β4), WPR (<i>n</i>β=β5).</p>d<p>Data based on national surveys from: AFR (<i>n</i>β=β15), AMR (<i>n</i>β=β9), EMR (<i>n</i>β=β13), SEAR (<i>n</i>β=β3), WPR (<i>n</i>β=β4).</p>e<p>Data based on national surveys from: AFR (<i>n</i>β=β0), AMR (<i>n</i>β=β1), EMR (<i>n</i>β=β0), SEAR (<i>n</i>β=β0), WPR (<i>n</i>β=β0).</p><p>AFR, Africa; AMR, Americas; EMR, Eastern Mediterranean; SEAR, Southeast Asia; WPR, Western Pacific.</p><p>WHO/HAI antibiotic pricing data for treatment of neonatal sepsis by WHO region.</p
Literature review: studies of diagnosis of possible bacterial infection/severe disease in newborns and young infants (<59 days).
a<p>Some studies did not report the exact breakdown of the bacterial infection diagnoses, but reported more generally on the illnesses detected. Hence, the <i>n</i>'s here do not necessarily add up to the <i>n</i> of those diagnosed as a bacterial infection by the gold standard.</p>b<p>**Data extracted from English 2003, which evaluated the same population but did not have the same exact sample size <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001741#pmed.1001741-English2" target="_blank">[68]</a>.</p><p>ANM, auxiliary nurse midwife; AWW, Anganwadi worker; NS, not stated.</p><p>Literature review: studies of diagnosis of possible bacterial infection/severe disease in newborns and young infants (<59 days).</p
Meta-analysis of the logit of the prevalence of non-prescription over-the-counter antibiotic use by young infants and children in low- and middle-income countries.
<p>Effect size is the Logit (prevalence of antibiotic purchases that were obtained over the counter without a prescription).</p
Receiver operating curve of studies of diagnostic accuracy of clinical sign algorithms versus physician-laboratory diagnosis of severe disease/pBI in young infants.
<p>Receiver operating curve of studies of diagnostic accuracy of clinical sign algorithms versus physician-laboratory diagnosis of severe disease/pBI in young infants.</p
Search strategy and results for literature review of published and grey literature.
<p>Search strategy and results for literature review of published and grey literature.</p
WHO/HAI data on antibiotic availability by WHO region.
<p>Availability defined as the percentage of medicine outlets surveyed with the particular antibiotic in stock at the time of the survey. Data are presented as median and range for data available from the respective WHO region. Data on procaine benzyl penicillin only available from 1 survey (Haiti).</p>a<p>Data based on national surveys from: AFR (<i>n</i>β=β4), AMR (<i>n</i>β=β1).</p>b<p>Data based on national surveys from: AFR (<i>n</i>β=β4), AMR (<i>n</i>β=β3), EMR (<i>n</i>β=β1), SEAR (<i>n</i>β=β2), WPR (<i>n</i>β=β1).</p>c<p>Data based on national surveys from: AFR (<i>n</i>β=β15), AMR (<i>n</i>β=β9), EMR (<i>n</i>β=β13), SEAR (<i>n</i>β=β3), WPR (<i>n</i>β=β4).</p>d<p>Data based on national surveys from: AFR (<i>n</i>β=β8), AMR (<i>n</i>β=β2), EMR (<i>n</i>β=β9), SEAR (<i>n</i>β=β4), WPR (<i>n</i>β=β5).</p>e<p>Data based on national surveys from: AFR (<i>n</i>β=β15), AMR (<i>n</i>β=β9), EMR (<i>n</i>β=β13), SEAR (<i>n</i>β=β4), WPR (<i>n</i>β=β5).</p><p>AFR, WHO African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EUR, European Region; SEAR, Southeast Asia Region; WPR, Western Pacific Region.</p><p>WHO/HAI data on antibiotic availability by WHO region.</p